Anti-membrane antibodies persist at least one year and discriminate between past COVID-19 infection and vaccination

Running head: Anti-membrane antibodies in COVID-19

Maya F. Amjadi[1], Ryan R. Adyniec[1], Srishti Gupta[1], S. Janna Bashar[1], Aisha M. Mergaert[1,2], Katarina M. Braun[3], Gage K. Moreno[2], David H. O'Connor[2], Thomas C. Friedrich[3], Nasia Safdar[1], Sara S. McCoy[1], Miriam A. Shelef[1,4*]

[1] Department of Medicine, University of Wisconsin (UW)-Madison, Madison, 53705 USA
[2] Department of Pathology and Laboratory Medicine, UW-Madison, Madison, 53705 USA
[3] Department of Pathobiological Sciences, UW-Madison, Madison, 53705 USA
[4] William S. Middleton Memorial Veterans Hospital, Madison, 53705 USA

***Corresponding author:**
Miriam A. Shelef
4130 MFCB
1685 Highland Avenue
Madison, WI 53705, USA
1 (608) 263-5241
mshelef@medicine.wisc.edu

Alternate corresponding author:
Maya F. Amjadi
Research Services
VA Medical Center Rm C3127
2500 Overlook Terrace
Madison WI 53705-2254
608-256-1901x17811
mamjadi@wisc.edu

(1) Declaration of Conflict of Interest

MFA, DHO, and MAS are listed as inventors on a patent filed related to this study (PCT/US2021/051143; IDENTIFICATION OF SARS-COV-2 EPITOPES DISCRIMINATING COVID-19 INFECTION FROM CONTROL AND METHODS OF USE). Promega provided Lumit™ SARS-CoV-2 Immunoassay kits.

(2) Financial Support

This work was supported by a Wisconsin Partnership Program COVID-19 Response grant (4647) and a UW Department of Medicine COVID-19 Pilot Award to MAS, by the CDC (75D30120C09870, 75D30121C11060) to DHO and TCF, and by NIAID (R24OD017850) to DHO. Additional support includes NIA (T32 AG000213) and MSTP (T32 GM140935) to MFA, NHLBI (T32 HL007899) to AMM, NCATS (1KL2TR002374) to SSM, and NIAID (1DP2AI144244-01) to NS. DHO and TCF are members of the Upper Midwest Regional Accelerator for Genomic Surveillance funded by the Rockefeller Foundation.

(3) Meetings at which all or part of the information has been presented

None

(4) To whom correspondence and requests for reprints should be addressed:

Miriam A. Shelef
4130 MFCB
1685 Highland Avenue
Madison, WI 53705, USA
1 (608) 263-5241
mshelef@medicine.wisc.edu

(5) Current affiliations for authors whose affiliations have changed since study completion

Aisha M. Mergaert, Labcorp Drug Development, 3301 Kinsman Blvd, Madison, WI 53704
Gage K. Moreno, Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142

Abstract

The consequences of past COVID-19 infection for personal and population health are emerging, but accurately identifying distant infection is a challenge. Anti-spike antibodies rise after both vaccination and infection and anti-nucleocapsid antibodies rapidly decline. We evaluated anti-membrane antibodies in COVID-19 naïve, vaccinated, and convalescent subjects to determine if they persist and accurately detect distant infection. We found that anti-membrane antibodies persist for at least a year and are a sensitive and specific marker of past COVID-19 infection. Thus, anti-membrane and anti-spike antibodies together can differentiate between COVID-19 convalescent, vaccinated, and naïve states to advance public health and research.

Keywords: antibody, SARS-CoV-2, COVID-19

Background

The cardinal features and challenges of the COVID-19 pandemic have changed. Initially, the pandemic was defined by SARS-CoV-2 infections in an immunologically naive population. Now, immunity from vaccination, infection, or both is common, reducing the severity of future infection waves. However, identifying infection for research and public health efforts is limited by the need to perform viral testing during acute infection (which may not occur during asymptomatic disease or pandemic surges that deplete resources) and by shortcomings in serologic testing [1]. Anti-nucleocapsid antibodies often decline to seronegativity just months after infection [2-4]. Anti-spike antibodies persist at least a year post-infection [5, 6] but typically cannot differentiate between infection and vaccination [7-9]. Anti-membrane antibodies develop soon after SARS-CoV-2 infection [10-12], but they are rarely assessed and their longevity is unknown. Here, we evaluated antibodies against the receptor binding domain (RBD) of spike, nucleocapsid, and membrane antigens in naïve, COVID-19 vaccinated, and COVID-19 convalescent subjects up to a year post symptom resolution to evaluate the persistence of anti-membrane antibodies and to identify antigens that discriminate between distant infection, vaccination, and naïve states.

Methods

Human subjects

Human studies were approved by the UW Institutional Review Board and human subjects provided written informed consent. Sera and data collected before 2019 from 60 COVID-19 naïve adults without inflammatory disease (exception: one subject with psoriatic arthritis using

adalimumab to match two COVID-19 convalescent subjects using adalimumab) were obtained from the University of Wisconsin (UW) Rheumatology Biorepository [13].

COVID-19 convalescent sera and data were obtained from the UW COVID-19 Convalescent Biorepository [14]. Briefly, in the spring of 2020, adults with a positive SARS-CoV-2 PCR test at UW Health were invited to participate until 121 subjects were recruited. Demographic and clinical information were collected by questionnaire and electronic medical record (EMR) abstraction. COVID-19 severity was diverse: mild (n=12), moderate (n=86), severe (n=15) and critical (n=8) as previously defined [14]. Subjects provided blood and clinical information 5 weeks (n=121), 3 months (n=115), 6 months (n=98) and 12 months (n=100) +/- 3 weeks after symptom resolution. One sample collected >3 weeks from the 3 month timepoint and subjects for whom the 5 week time point was collected >3 weeks from the intended timepoint (n=1) or missed >1 blood draw (n=16) were excluded from comparative analyses, generating sample sizes of 104 (5 weeks), 101 (3 months), 97 (6 months), and 98 (12 months). Based on anti-RBD Ig elevation timing post-vaccination (Supplementary Figure 1), COVID-19 convalescent subjects at 12 months were considered vaccinated if they received 1 vaccine dose $\geq$5 days before sample collection (n=77) and unvaccinated (n=21) if they received no vaccine (n=17) or their first or only vaccine dose <5 days before sample collection (n=4).

Vaccinated individuals without past COVID-19 (n=21) were recruited by flyers at UW Health in summer of 2021. Complete vaccination (>3 weeks after two mRNA vaccine doses or one Ad26.COV2.S dose) and lack of known COVID-19 was confirmed by questionnaire and EMR review.

Limited clinical data, sera, and SARS-CoV-2 lineages were provided by UW Health Infection Control for 20 completely vaccinated healthcare workers with breakthrough COVID-19 (positive PCR and symptoms) in the spring of 2021. Blood collection occurred ~1 day after SARS-CoV-2 PCR (range 0-4 days) and ~3 days after symptom onset (range 0-5 days). Four breakthrough cases also had PCR positive COVID-19 prior to vaccination completion and 3-6 months prior to breakthrough infection. Healthcare workers with breakthrough infections were invited to participate in the longitudinal study, and 3 provided blood ~8 weeks (range 37-70 days) after the initial collection.

Anti-RBD Ig *Immunoassay*

Anti-RBD Ig was detected by Lumit™ SARS-CoV-2 Immunoassay (Promega, Madison, WI) according to kit instructions using a TEMPEST® Liquid Handler (Formulatrix, Bedford, MA) and a PHERAstar FS plate reader (BMG Labtech, Ortenberg, Germany). Sera were diluted 1:10 to use the kit's recommended sample/calibrator cutoff of 1 for seropositivity. At 1:10, the highest anti-RBD Ig values were above the linear range, but results were overall similar to a 1:200 dilution (Supplementary Figure 2), at which higher values were within the linear range.

Anti-membrane and anti-nucleocapsid IgG ELISA

ELISAs were performed as previously to detect IgG against SARS-CoV-2 membrane (aa 8-23, ITVEELKKLLEQWNLV-K-biotin) and nucleocapsid (aa 390-405, QTVTLLPAADLDDFSK-K-biotin) peptides [10] with the following modifications: blocking for >2.5 instead of 1 hour and serum dilution of 1:50 (nucleocapsid) or 1:500 (membrane), instead of 1:200 to maximally

utilize the linear range. Relative absorbance values (IgG binding to uncoated wells subtracted from coated wells for each subject and values normalized across plates using a serum standard) of 0 were plotted as 0.0001 to allow a log scale for graphs.

Statistics

Statistical analyses were performed using Prism (GraphPad, San Diego, CA) and JMP (SAS Institute, Cary, NC) software. Antibody levels were compared between naïve or vaccinated subjects versus all other groups by Kruskal-Wallis One-Way ANOVA with Dunn's multiple comparisons test. Antibody levels in unvaccinated versus vaccinated 12 month convalescent samples were compared by Mann-Whitney U test. Matched antibody levels across multiple timepoints in convalescent subjects were compared by Friedman test with Dunn's multiple comparisons test. Antibody levels in breakthrough infection subjects were compared at ~3 days post symptom onset versus ~8 weeks later by Wilcoxon signed rank test. Antibody positivity was compared between two groups with Fisher's exact test and among multiple groups with a chi-square test. P values <0.05 were considered significant.

Results

We quantified antibodies against RBD, nucleocapsid, and membrane antigens in sera from the following subjects: naïve, vaccinated with no known COVID-19 infection, COVID-19 convalescent with sera collected 5 weeks, 3 months, 6 months, and 12 months post symptom resolution (all initially unvaccinated), and vaccinated with subsequent SARS-CoV-2 breakthrough infection. Clinical and demographic information is in Supplementary Table 1.

For anti-RBD Ig, the chemiluminescent assay had an area under the receiver operator curve (AUC) of 0.973, 90% sensitivity, and 97% specificity (Supplementary Figure 3A), comparable to other assays [14]. Convalescent and vaccinated individuals had significantly higher anti-RBD Ig than naïve subjects, with no significant difference in antibody levels or percent seropositivity between vaccinated subjects and unvaccinated convalescent subjects (Figure 1A and 1B). In a matched analysis of the 88 subjects who provided serum at all 4 timepoints (Figure 1C), anti-RBD Ig levels were statistically different between timepoints, but the extremely small difference in medians seems unlikely to be biologically meaningful. Further, the percent of seropositive subjects at 5 weeks (91%) versus 6 months (88%) was not significantly different (Figure 1B). Because only 21 convalescent subjects remained unvaccinated at 12 months, this timepoint was not compared to the 5 week timepoint. Not surprisingly, anti-RBD Ig levels in 12 month convalescent subjects were significantly higher for those who received at least one dose of a vaccine compared with no vaccine (Figure 1A and Supplementary Figure 1B). Finally, all vaccinated subjects, with or without past or breakthrough infections, were seropositive for anti-RBD Ig, with no significant differences in antibody levels between vaccinated subjects with or without breakthrough infections (Figure 1A and 1B). Overall, these data suggest that anti-RBD antibodies are detectable in the vast majority of vaccinated and convalescent subjects at least a year after infection, but cannot differentiate between past infection, vaccination, and vaccination with breakthrough infection.

Next, we evaluated anti-nucleocapsid IgG. The ELISA had an AUC of 0.919, 91% sensitivity, and 88% specificity (Supplementary Figure 3B). The low specificity of this test is consistent with other anti-nucleocapsid tests, likely due to cross-reactivity with common cold coronavirus

nucleocapsid [14, 15]. Nonetheless, as expected, there was no difference in anti-nucleocapsid IgG levels between naïve versus vaccinated subjects or between 12 month convalescent vaccinated versus unvaccinated subjects (Figure 1D). Also as expected, compared to either vaccinated or naïve subjects, anti-nucleocapsid IgG levels were higher in subjects with past infection (Figure 1D). However, in a matched analysis of convalescent subjects, anti-nucleocapsid IgG levels fell significantly over time (Figure 1F) with 34% of subjects seronegative by 6 months and 48% by 12 months, a significant increase in seronegativity compared to 8% at 5 weeks (Figure 1E). Interestingly, none of the four breakthrough cases who also had COVID-19 before vaccination were seropositive for anti-nucleocapsid IgG at the time of breakthrough infection and only one of three subjects was seropositive eight weeks after breakthrough infection (Figure 1E). Together, these data highlight the rapid decline of anti-nucleocapsid antibodies.

Last, we evaluated anti-membrane IgG. The ELISA had an AUC of 0.956, 88% sensitivity, and 95% specificity (Supplementary Figure 3C). As expected, anti-membrane IgG levels and percent seropositivity did not differ between naïve and vaccinated subjects (or between 12 month convalescent vaccinated and unvaccinated subjects), but were significantly higher in convalescent subjects (Figure 1G and 1H). In a matched analysis over time (Figure 1I), anti-membrane IgG levels remained stable at 6 months with an extremely small decline at 12 months. However, at 12 months, 94% of convalescent samples were seropositive for anti-membrane IgG, as compared to 88% at 5 weeks (Figure 1H). Interestingly, all four vaccine breakthrough infection subjects with prior COVID-19 and no breakthrough subjects without prior COVID-19 were seropositive for anti-membrane IgG during acute infection (Figure 1H). Together, these

data demonstrate that anti-membrane IgG persists at least a year and can be a sensitive and specific marker of past COVID-19 infection.

Finally, we compared antibody levels at 5 weeks and 12 months post COVID-19 across disease severity groups. As expected [10, 14], levels of all three antibodies were generally higher in subjects with more severe COVID-19 at both time points, except anti-nucleocapsid IgG at 12 months (Figure 2).

Discussion

Here, in addition to confirming that anti-RBD antibodies last at least a year and anti-nucleocapsid IgG declines over months [2-6], we demonstrate that anti-membrane IgG is present in the vast majority of COVID-19 convalescent patients and persists at least a year. Our findings are consistent with findings for IgG against a recombinant membrane antigen (polypeptide of aa 1-19 and 101-222) in the early convalescent period [11]. In contrast, Jörrißen and colleagues found that only ~20% of non-hospitalized COVID-19 convalescent subjects had IgG against a membrane peptide in the early convalescent period [12]. Our non-hospitalized subjects alone were 88% positive for anti-membrane IgG at 5 weeks (n=83) and 94% at 12 months (n=77) post COVID-19. This discrepancy may be due to their smaller sample size (n=30) or use of a different peptide (aa 1-20).

Given the absence of anti-RBD and anti-membrane antibodies in naïve subjects, the presence of only anti-RBD antibodies in vaccinated subjects, and the presence of both in COVID-19 convalescent subjects up to 12 months after infection, our study suggests that a combination of

anti-RBD and anti-membrane antibody testing could be used to detect past COVID-19 infection and vaccination at a population and individual level. An analogous testing strategy for hepatitis B uses anti-surface antibodies to detect past infection or vaccination and anti-core antibodies to detect past infection. While SARS-CoV-2 does not appear to cause persistent infection like hepatitis B, the long-term consequences of COVID-19 are still emerging and revealing a previously undetected infection may prove important. At minimum, detecting unknown past infections may relieve personal anxiety about future infections in some individuals. Moreover, accurate assessment of past infection in a population could enhance the prediction of and interpretation of COVID-19 surge outcomes and inform public health policy.

Limitations of this study include that samples were collected only up to 12 months post COVID-19 and that we quantified IgG, not IgM or IgA, that binds membrane and nucleocapsid peptides versus total Ig that binds RBD. Also, subjects were infected by ancestral SARS-CoV-2 lineages (early 2020) or alpha and delta variants (breakthrough infections, Supplementary Figure 4), whereas the omicron variant has a single amino acid difference in the membrane peptide (ITVEELKKLLEEWNLV). Finally, sample sizes for breakthrough infections were small with samples collected ~3 days after symptom onset, possibly allowing an early antibody response. Future studies are needed to evaluate later time points, multiple antibody isotypes, larger cohorts, and antibodies after omicron infections.

Nonetheless, we demonstrate that anti-membrane antibodies persist at least a year and, together with anti-RBD antibodies, can accurately identify past-COVID-19 infection and vaccination.

Funding

This work was supported by a Wisconsin Partnership Program COVID-19 Response grant [4647] and a UW Department of Medicine COVID-19 Pilot Award to MAS, by the CDC [75D30120C09870, 75D30121C11060] to DHO and TCF, and by NIAID [R24OD017850] to DHO. Additional support includes NIA [T32 AG000213] and MSTP [T32 GM140935] to MFA, NHLBI [T32 HL007899] to AMM, NCATS [1KL2TR002374] to SSM, and NIAID [1DP2AI144244-01] to NS. DHO and TCF are members of the Upper Midwest Regional Accelerator for Genomic Surveillance funded by the Rockefeller Foundation.

Acknowledgements

The authors thank Gene Ananiev and Song Guo at UW's Small Molecules Screening Facility and Laura Perez-Brenner, Samantha Lewis and Melanie Dart from Promega for technical advice, UW Health Infection Control and Employee Health Services, the UW Clinical Research Office, and the participating human subjects.

Conflicts of Interest

MFA, DHO, and MAS are listed as inventors on a patent filed related to this study (PCT/US2021/051143; IDENTIFICATION OF SARS-COV-2 EPITOPES DISCRIMINATING COVID-19 INFECTION FROM CONTROL AND METHODS OF USE). Promega provided Lumit™ SARS-CoV-2 Immunoassay kits.

References

1. Gong F, Wei HX, Li Q, Liu L, Li B. Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis. Front Mol Biosci **2021**; 8:682405.
2. Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity **2020**; 53:925-33.e4.
3. Liu A, Li Y, Peng J, Huang Y, Xu D. Antibody responses against SARS-CoV-2 in COVID-19 patients. J Med Virol **2020**.
4. Bolotin S, Tran V, Osman S, et al. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline. J Infect Dis **2021**; 223:1334-8.
5. Gallais F, Gantner P, Bruel T, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine **2021**; 71:103561.
6. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature **2021**; 595:426-31.
7. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature **2021**; 592:616-22.
8. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med **2021**; 384:2259-61.
9. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med **2021**; 384:2187-201.
10. Heffron AS, McIlwain SJ, Amjadi MF, et al. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol **2021**; 19:e3001265.

11. Lopandić Z, Protić-Rosić I, Todorović A, et al. IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein. Int J Mol Sci **2021**; 22.
12. Jörrißen P, Schütz P, Weiand M, et al. Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. Front Immunol **2021**; 12:679841.
13. Holmes CL, Peyton CG, Bier AM, et al. Reduced IgG titers against pertussis in rheumatoid arthritis: Evidence for a citrulline-biased immune response and medication effects. PLoS One **2019**; 14:e0217221.
14. Amjadi MF, O'Connell SE, Armbrust T, et al. Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. Immunohorizons **2021**; 5:466-76.
15. Noda K, Matsuda K, Yagishita S, et al. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci Rep **2021**; 11:5198.

Figure Legend

Figure 1. Anti-RBD, anti-nucleocapsid, and anti-membrane antibodies after COVID-19 vaccination and infection. Anti-RBD Ig was detected by immunoassay (reported as sample/calibrator, S/C) and anti-nucleocapsid and anti-membrane IgG were quantified by ELISA (reported as relative absorbance, rel. abs.) in sera from the following subjects: naive (n=60), vaccinated with no known COVID-19 infection (Vax, n=21), COVID-19 convalescent 5 weeks (5w, n=104), 3 months (3m, n=101), 6 months (6m, n=97), and 12 months (12m, n=98) post-symptom resolution either vaccinated (12m Vax, n=77) or not (12m Unvax, n=21), vaccinated with breakthrough COVID-19 ~3 days (Vax BT ~3d, n=20) and ~8 weeks (Vax BT ~8w, n=3) after symptom onset including 4 subjects with previous COVID-19 infection (PI). Anti-RBD Ig (A), anti-nucleocapsid IgG (D), and anti-membrane IgG (G) levels for all groups were graphed and compared to naive (blue) or Vax (gray) by Kruskal-Wallis and Dunn's multiple comparisons tests and 12m Unvax was compared to 12m Vax by Mann-Whitney test (brackets). Vax BT with both ~3d and ~8w timepoints are represented with triangles or squares and Vax BT subjects with PI in red symbols. Percent positive (black) and negative (gray) for anti-RBD Ig (B), anti-nucleocapsid IgG (E), and anti-membrane IgG (H) were graphed and compared between selected groups by Fisher's exact (line) or chi-square (bracket encompassing compared groups) tests. Matched anti-RBD Ig (C), anti-nucleocapsid IgG (F) and anti-membrane IgG (I) levels were compared across timepoints for COVID-19 convalescent subjects (n=88) by Friedman test with Dunn's multiple comparisons test. For top and bottom panels: bars indicate medians, and dashed lines indicate cutoffs. For all panels: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, or not significant (ns).

Figure 2. Anti-SARS-CoV-2 antibody levels are higher after more severe COVID-19. Anti-RBD Ig (A), anti-nucleocapsid IgG (B), and anti-membrane IgG (C) were compared across disease severity groups by Kruskal-Wallis with Dunn's Multiple Comparisons test at indicated time points (mild: n=11 5w, n=10 6m, n=9 12m; moderate (mod.): n=72 5w, n=68 6m and 12m; severe: n=15 5w, n=13 6m, n=15 12m; critical: n=6 5w, 6m, and 12m). For all panels: bars represent medians, dashed lines indicate cutoffs, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.



Figure 1
25x25 mm (.33 x DPI)



Figure 2
25x25 mm (.33 x DPI)